The Q·Score Snapshot
LLY scores 8 out of 10, carrying a "Bullish" Q·Score label. The Q·Score is Quantify's composite signal, aggregating fundamentals, growth momentum, analyst sentiment, and valuation metrics into a single number — a score of 8 reflects that the data across most of those dimensions is pointing in the same direction. It describes what the numbers show collectively, not a directive on what to do with the stock.
Business at a Glance
Eli Lilly is a global pharmaceutical giant headquartered in Indianapolis, operating within the Healthcare sector and focused on drug discovery, development, and commercialization. The company's current data profile is being shaped overwhelmingly by the explosive commercial success of its GLP-1 receptor agonist franchise — most notably tirzepatide, marketed for type 2 diabetes and obesity under the brands Mounjaro and Zepbound. That single product category has functionally rewritten Lilly's financial trajectory over the past two years, driving the kind of top- and bottom-line growth figures that are rare at a company of this scale.
The Numbers That Stand Out
Revenue growth of 55.5% year-over-year is extraordinary for a company with a market capitalisation exceeding $1 trillion — at that size, moving the needle even modestly requires billions in incremental sales. Earnings growth of 169.9% suggests that revenue is not just growing but converting into profit at an accelerating rate, supported by a net profit margin of 35%, meaning roughly $0.35 of every dollar in revenue flows through to the bottom line. Return on equity (ROE) — a measure of how efficiently a company generates profit from shareholders' invested capital — stands at 107.5%, a figure that reflects both high profitability and the financial leverage embedded in Lilly's balance sheet. The forward P/E of 25.5 (the stock price divided by the next twelve months' expected earnings per share) is notably moderate relative to the growth rates on display, a data point that analysts and quantitative models tend to flag. The 100% EPS beat rate means Lilly has not missed a single consensus earnings estimate across the periods tracked — a consistency that is statistically uncommon among mega-cap peers.
What Analysts Think
Of the 26 analysts currently covering LLY, 79% carry a positive rating on the stock — indicating that the clear majority of professional coverage leans bullish on the name. The consensus price target implies approximately 11.2% upside from the current price of $1,148.84, which would place the analyst consensus target in the vicinity of $1,277. The remaining 21% of covering analysts are either neutral or negative, suggesting the consensus, while skewed positive, is not unanimous.
The Bigger Picture
Within the Healthcare sector, Eli Lilly has moved from a well-regarded mid-tier pharmaceutical name to what the data now describes as a category-defining outlier — its growth metrics sit at the far right tail of the distribution for large-cap pharma globally. The GLP-1 obesity and diabetes market is still in a relatively early commercial phase, and Lilly's manufacturing scale-up has been a central narrative in how the company's financials have evolved quarter to quarter. Whether the current growth trajectory is durable, or whether competitive dynamics from peers like Novo Nordisk begin to compress margins and market share, remains the central question the data will answer over the coming reporting periods.